Haslev, Denmark

John Paul Kilburn

USPTO Granted Patents = 29 

 

 

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 44(Granted Patents)


Location History:

  • Haslev, DK (2011 - 2019)
  • Valby, DK (2022)

Company Filing History:


Years Active: 2011-2022

Loading Chart...
Loading Chart...
Loading Chart...
29 patents (USPTO):Explore Patents

Sure, I can help you with that. Here is an article about inventor John Paul Kilburn:

Title: John Paul Kilburn: Pioneer in NMDA Receptor Modulation

Introduction:

John Paul Kilburn, a notable inventor hailing from Haslev, Denmark, has made significant contributions to the field of neurological and neuropsychiatric disorders through his innovative patents and research. With an impressive portfolio of 29 patents, Kilburn continues to push the boundaries of treatment options for conditions such as depression.

Latest Patents:

Kilburn's recent patents focus on modulators of the NMDA receptor, a key target in the treatment of neurological and neuropsychiatric disorders. These novel compounds offer promising therapeutic potential and have paved the way for the development of pharmaceutical compositions aimed at addressing conditions like depression. Additionally, his work on prodrugs of NMDA receptor modulators showcases his dedication to advancing drug delivery mechanisms for improved efficacy.

Career Highlights:

Throughout his career, Kilburn has showcased his expertise by working with renowned companies in the pharmaceutical industry. Notable among these are H. Lundbeck A/S and High Point Pharmaceuticals, LLC, where he has played a pivotal role in driving innovation and drug development. His collaborations with leading researchers and experts have further solidified his position as a visionary in the field.

Collaborations:

Kilburn's collaborations with esteemed colleagues like Jan Kehler and Jacob Nielsen have been instrumental in his success as an inventor. Together, they have combined their unique skills and insights to create groundbreaking solutions for complex medical challenges. Their collective efforts underscore the importance of collaboration in driving meaningful innovation.

Conclusion:

In conclusion, John Paul Kilburn's dedication to advancing the field of neurological and neuropsychiatric disorders is truly commendable. Through his pioneering work on NMDA receptor modulation and drug development, he continues to make a lasting impact on healthcare and patient outcomes. We look forward to witnessing his future contributions and the positive influence they will have on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…